{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:12:52Z","timestamp":1787883172109,"version":"build-2784847793"},"reference-count":12,"publisher":"Becaris Publishing Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,5]]},"abstract":"\n Aim:<\/jats:bold>\n Despite the availability of novel treatment options for patients with triple-class exposed\/refractory multiple myeloma , there is a lack of consensus on the optimal regimen. A previous unanchored matching-adjusted indirect comparison (MAIC) of the MagnetisMM-3 (\n NCT04649359<\/jats:ext-link>\n ) and LocoMMotion (\n NCT04035226<\/jats:ext-link>\n ) study reported significant improvements in progression-free survival (PFS) and overall survival (OS) with elranatamab versus physician\u2019s choice of treatment.\n Materials & methods:<\/jats:bold>\n We conducted an updated MAIC based on more recent data (28.4\u00a0months for MagnetisMM-3). Following reweighting of MagnetisMM-3 individual patient data to match the LocoMMotion population, the effective sample size was 64 for PFS and 63 for OS in the base-case analysis.\n Results:<\/jats:bold>\n Consistent with the original MAIC, significantly improved PFS (hazard ratio [HR] [95% confidence interval (CI)]: 0.32 [0.21, 0.50], p\u00a0<\u00a00.01) and OS (HR [95% CI]: 0.50 [0.33, 0.78], p\u00a0<\u00a00.01) were observed with elranatamab versus physician\u2019s choice of treatment. The robustness of the results was demonstrated in sensitivity analyses in which missing baseline characteristics data for elranatamab were imputed.\n Conclusion:<\/jats:bold>\n Overall, the findings of this study align with and add confidence to the conclusions of the previous MAIC that elranatamab is associated with significantly improved outcomes versus standard treatment, supporting the value to elranatamab for the treatment of patients with triple-class exposed\/refractory multiple myeloma.\n <\/jats:p>","DOI":"10.57264\/cer-2024-0236","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T04:52:14Z","timestamp":1744001534000},"source":"Crossref","is-referenced-by-count":5,"title":["Elranatamab versus physician\u2019s choice of treatment in patients with triple-class exposed\/refractory multiple myeloma: an updated matching-adjusted indirect comparison"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6366-9178","authenticated-orcid":false,"given":"Isha","family":"Mol","sequence":"first","affiliation":[{"name":"Cytel, Inc., Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannan","family":"Hu","sequence":"additional","affiliation":[{"name":"Cytel, Inc., Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-7895","authenticated-orcid":false,"given":"Thomas W","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapy, Duke University School of Medicine, Durham, NC 27705, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C","family":"Cappelleri","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, CT 06340, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0932-598X","authenticated-orcid":false,"given":"Haitao","family":"Chu","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY 10001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Nador","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Tadworth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didem","family":"Aydin","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel Perez","family":"Cruz","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY 10001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hlavacek","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY 10001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_7_3_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","article-title":"Treatment options for triple-class refractory multiple myeloma","volume":"20","author":"Mikhael J","year":"2020","unstructured":"Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk. 20(1), 1\u20137 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"8","key":"e_1_3_7_4_2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi NC","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384(8), 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"10297","key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase Ib\/II open-label study","volume":"398","author":"Berdeja JG","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase Ib\/II open-label study. Lancet 398(10297), 314\u2013324 (2021).","journal-title":"Lancet"},{"issue":"24","key":"e_1_3_7_6_2","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari A","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N. Engl. J. Med. 387(24), 2232\u20132244 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"e_1_3_7_7_2","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase II MagnetisMM-3 trial results","volume":"29","author":"Lesokhin AM","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B Elranatamab in relapsed or refractory multiple myeloma: phase II MagnetisMM-3 trial results. Nat. Med. 29(9), 2259\u20132267 (2023).","journal-title":"Nat. Med."},{"key":"e_1_3_7_8_2","unstructured":"US Food and Drug Administration. Highlights of prescribing information. ELREXFIO (elranatamab-bcmm) injection for subcutaneous use. Initial US approval: 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761345s000lbl.pdf"},{"issue":"12","key":"e_1_3_7_9_2","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/s41375-024-02404-6","article-title":"LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed\/refractory multiple myeloma \u2013 2-year follow-up (final analysis)","volume":"38","author":"Mateos MV","year":"2024","unstructured":"Mateos MV, Weisel K, De Stefano V LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed\/refractory multiple myeloma \u2013 2-year follow-up (final analysis). Leukemia 38(12), 2554\u20132560 (2024).","journal-title":"Leukemia"},{"key":"e_1_3_7_10_2","unstructured":"Phillippo D Ades T Dias S Palmer S Abrams KR Welton N. NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submissions to NICE. (2016). Available from: https:\/\/research-information.bris.ac.uk\/ws\/portalfiles\/portal\/94868463\/Population_adjustment_TSD_FINAL.pdf"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2277850"},{"issue":"7","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1002\/hem3.136","article-title":"Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3 study","volume":"8","author":"Tomasson MH","year":"2024","unstructured":"Tomasson MH, Iida S, Niesvizky R Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3 study. Hemasphere 8(7), e136 (2024).","journal-title":"Hemasphere"},{"issue":"2","key":"e_1_3_7_13_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo DM","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med. Decis. Making 38(2), 200\u2013211 (2018).","journal-title":"Med. Decis. Making"},{"issue":"1","key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41408-024-01200-w","article-title":"Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM","volume":"14","author":"Malard F","year":"2024","unstructured":"Malard F, Bobin A, Labopin M Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM. Blood Cancer J. 14(1), 219 (2024).","journal-title":"Blood Cancer J."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T04:47:11Z","timestamp":1744778831000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.57264\/cer-2024-0236"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0236","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"article-number":"e240236"}}